Indian per capita income increase will lead to increased spending on healthcare and medicines, including both generic and non-generic products. The generic market is attractive, projected to be around $600 billion in 2030. MNCs focus on proprietary products, taking advantage of improved GDP and per capita income. Indian companies are engaged in complex generics and biosimilars research, with potential for huge benefits. Patent expirations in 2025 will create opportunities for Indian companies.
Related Keywords
India , Kozhikode , Kerala , Lucknow , Uttar Pradesh , Kewal Handa , Offering College , Pfizer , Biocon , Industry Expert , Leadership Excellence , Marketing Officer , Product Officer , Executive Officer , Might Also Like , Every Indian , Pharma Stocks To Buy , Cost Benefit Analysis , Sun Pharma Zydus Intas , Complex Generics Biosimilars Api , Mylan , Expert View , Stock Market , Et Now ,
vimarsana.com © 2020. All Rights Reserved.